NCI Drug Discovery Program Pays Off

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

ROCKVILLE, Md--Bruce Chabner, MD, director of the NCI Division of Cancer Treatment, said that over the past decade, NCI's drug discovery and development programs have produced seven new drugs currently being used to treat cancer and AIDS. The program cost about $1.4 billion: $200 million for every New Drug Application filed.

ROCKVILLE, Md--Bruce Chabner, MD, director of the NCI Divisionof Cancer Treatment, said that over the past decade, NCI's drugdiscovery and development programs have produced seven new drugscurrently being used to treat cancer and AIDS. The program costabout $1.4 billion: $200 million for every New Drug Applicationfiled.

Dr. Chabner made the report to the National Cancer Advisory Board'sAd Hoc Working Group on NCI Intramural Programs. He added thatduring the decade, increases in AIDS research funding has hada significant effect on the intramural research program. "Intramuralscientists have shifted the focus of their research to followthe money," he said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.